NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Descending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
69539-0181-01 | 69539-0181 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 10, 2020 | In Use | |
72205-0054-01 | 72205-0054 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | May 12, 2020 | In Use | |
69539-0034-01 | 69539-0034 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 5, 2019 | In Use | |
31722-0165-31 | 31722-0165 | Fosaprepitant dimeglumine | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | July 29, 2021 | In Use | |
72205-0083-01 | 72205-0083 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | May 12, 2020 | In Use | |
00006-3941-01 | 00006-3941 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov. 19, 2010 | In Use | |
00006-3941-32 | 00006-3941 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov. 12, 2010 | In Use | |
57277-0106-15 | 57277-0106 | carboplatin Injection | Carboplatin | 150.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 29, 2016 | In Use | |
67457-0889-10 | 67457-0889 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 5, 2019 | In Use | |
69097-0830-37 | 69097-0830 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 5, 2019 | In Use | |
71839-0104-01 | 71839-0104 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Oct. 15, 2019 | In Use | |
70710-1615-01 | 70710-1615 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov. 1, 2020 | In Use | |
63323-0972-10 | 63323-0972 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 5, 2019 | In Use | |
55150-0299-01 | 55150-0299 | Fosaprepitant dimeglumine | Fosaprepitant dimeglumine | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jan. 12, 2021 | In Use | |
72205-0026-01 | 72205-0026 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 5, 2019 | In Use | |
82243-1001-01 | 82243-1001 | FOSAPREPITANT | FOCINVEZ | 150.0 mg/50mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Aug. 30, 2023 | In Use | |
50742-0446-15 | 50742-0446 | Carboplatin | Carboplatin | 150.0 mg/15mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 6, 2017 | Feb. 12, 2018 | In Use |
24987-0111-14 | 24987-0111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 15, 2013 | Aug. 31, 2017 | No Longer Used |
24987-0111-15 | 24987-0111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct. 25, 2013 | July 7, 2014 | No Longer Used |
59212-0111-10 | 59212-0111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jan. 1, 2016 | Oct. 25, 2018 | In Use |
59212-0111-14 | 59212-0111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 15, 2013 | In Use | |
82454-0212-03 | 82454-0212 | Nilutamide | Nilutamide | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Nov. 22, 2019 | In Use | |
00378-9045-01 | 00378-9045 | Cysteamine bitartrate | Cystagon | 150.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Aug. 15, 1994 | Sept. 4, 2018 | In Use | |
00378-9045-05 | 00378-9045 | Cysteamine bitartrate | Cystagon | 150.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | April 11, 2005 | In Use | ||
59651-0532-03 | 59651-0532 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | June 22, 2022 | In Use |
Found 10,000 results in 12 milliseconds — Export these results